Seelos Therapeutics Inc.
13F holders, Q2 2024 (June 30)21holders
$0.61avg. 13F price*
At the end of Q2 2024, 21 institutions reported holding Seelos Therapeutics Inc. in their 13F filings. The largest holders were AdvisorShares Investments LLC ($56K), Wealth Effects LLC ($32K) and Morgan Stanley ($13K).
- Company
- Seelos Therapeutics Inc.
- CUSIP
- 81577F307
- Latest filing quarter
- Q2 2024
Total Exit/New Position Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $5 |
| Exits | 0 | $0 |
Ownership 21 holders
| AdvisorShares Investments LLC | 0.01% | Add +55.3% | 89,812 | $56K |
| Wealth Effects LLC | 0.01% | Reduce -7.7% | 53,844 | $32K |
| Morgan Stanley | 0.00% | Add +41.3% | 22,271 | $13K |
| Modera Wealth Management, LLC | 0.00% | Add +8.3% | 21,336 | $13K |
| Geode Capital Management, LLC | 0.00% | No change | 12,797 | $8K |
| BlackRock Inc. | 0.00% | Reduce -0.3% | 6,975 | $4K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +193.5% | 3,859 | $2K |
| Carmichael Hill & Associates, Inc. | 0.00% | No change | 1,000 | $597 |
| JPMorgan Chase & Co. | 0.00% | Reduce -0.6% | 501 | $300 |
| Bank of America Corp. | 0.00% | Add +0.5% | 472 | $282 |
| Group One Trading LLC | 0.00% | Reduce -5.3% | 216 | $129 |
| Vermillion & White Wealth Management Group, LLC | 0.00% | Reduce -1.2% | 123 | $73 |
| Crewe Advisors LLC | 0.00% | Reduce -0.5% | 115 | $69 |
| UBS Group AG | 0.00% | Reduce -96.1% | 50 | $30 |
| Wells Fargo & Company | 0.00% | Reduce -25.4% | 41 | $24 |
| NFSG Corp | 0.00% | Reduce -3.5% | 24 | $14 |
| TD Waterhouse Canada Inc. | 0.00% | New | 8 | $5 |
| PNC Financial Services Group, Inc. | 0.00% | Add +33.3% | 2 | $2 |
| National Bank of Canada | 0.00% | Reduce -3.0% | 4 | $2 |
| Westside Investment Management, Inc. | 0.00% | Reduce -3.0% | 4 | $2 |
| BNP Paribas Financial Markets | 0.00% | Add +166.7% | 1 | $1 |
"% of holder's portfolio" is SEELOS THERAPEUTICS INC's weight in each manager's 13F, not the share of Seelos Therapeutics Inc. the manager owns.